T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortinet
FTNT
|
+$2.03B |
| 2 |
Rockwell Automation
ROK
|
+$1.44B |
| 3 |
Autodesk
ADSK
|
+$1.15B |
| 4 |
Citigroup
C
|
+$975M |
| 5 |
ConocoPhillips
COP
|
+$967M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.59B |
| 2 |
GE Aerospace
GE
|
+$1.78B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.38B |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 5 |
Philip Morris
PM
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.21% |
| 2 | Healthcare | 15.42% |
| 3 | Financials | 10.99% |
| 4 | Consumer Discretionary | 10.39% |
| 5 | Communication Services | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Prime Medicine
PRME
$575M
| $17.7M | ﹤0.01% |
2,522,590
+301,431
| +14% | +$2.29M |
|
1002
Pharvaris
PHVS
$2.38B
| $17.5M | ﹤0.01% |
757,915
-84,783
| -10% | -$2.25M |
|
1003
Graco
GGG
$13.3B
| $17.5M | ﹤0.01% |
187,354
-8,226
| -4% | -$728K |
|
1004
Tenaya Therapeutics
TNYA
$164M
| $17.5M | ﹤0.01% |
3,346,522
-1,198,021
| -26% | -$5.73M |
|
1005
Teradata
TDC
$2.57B
| $17.4M | ﹤0.01% |
449,954
-169,890
| -27% | -$7.16M |
|
1006
Carlisle Companies
CSL
$14.9B
| $17.4M | ﹤0.01% |
44,381
+1,429
| +3% | +$485K |
|
1007
Jack Henry & Associates
JKHY
$11.1B
| $17.3M | ﹤0.01% |
99,707
+1,397
| +1% | +$238K |
|
1008
C4 Therapeutics
CCCC
$502M
| $17.3M | ﹤0.01% |
2,115,477
-443,003
| -17% | -$3.43M |
|
1009
Coty
COTY
$2.42B
| $17.3M | ﹤0.01% |
1,443,577
-695,982
| -33% | -$8.5M |
|
1010
Gibraltar Industries
ROCK
$1.45B
| $17.2M | ﹤0.01% |
214,150
-1,628
| -0.8% | -$130K |
|
1011
Fortune Brands Innovations
FBIN
$5.78B
| $17.2M | ﹤0.01% |
203,630
-3,666
| -2% | -$291K |
|
1012
Alliant Energy
LNT
$18.2B
| $17.1M | ﹤0.01% |
339,408
+7,100
| +2% | +$348K |
|
1013
A10 Networks
ATEN
$1.96B
| $17M | ﹤0.01% |
1,242,792
+34,115
| +3% | +$459K |
|
1014
iShares MSCI EAFE ETF
EFA
$80.3B
| $16.9M | ﹤0.01% |
211,128
+9,204
| +5% | +$704K |
|
1015
Universal Health Services
UHS
$10.1B
| $16.8M | ﹤0.01% |
92,215
-1,234
| -1% | -$204K |
|
1016
Cadre Holdings
CDRE
$1.45B
| $16.7M | ﹤0.01% |
460,500
+113,722
| +33% | +$3.96M |
|
1017
Symbotic
SYM
$5.43B
| $16.6M | ﹤0.01% |
369,646
+620
| +0.2% | +$27.2K |
|
|
JNPR
1018
DELISTED
Juniper Networks
JNPR
| $16.4M | ﹤0.01% |
443,713
-1,144
| -0.3% | -$41.8K |
|
|
FOLD
1019
DELISTED
Amicus Therapeutics
FOLD
| $16.4M | ﹤0.01% |
1,389,361
+12,003
| +0.9% | +$154K |
|
|
APO.PRA
1020
DELISTED
Apollo Global Management Series A
APO.PRA
| – | – |
0
| – | – |
|
1021
AES
AES
$10.5B
| $16.3M | ﹤0.01% |
907,170
-5,764
| -0.6% | -$96.3K |
|
1022
BrightSpring Health Services
BTSG
$11.9B
| $16.3M | ﹤0.01% |
+1,495,724
| New | +$15M |
|
1023
Eastman Chemical
EMN
$8.43B
| $16M | ﹤0.01% |
159,474
+750
| +0.5% | +$66K |
|
1024
Autoliv
ALV
$8.89B
| $15.9M | ﹤0.01% |
132,341
+4,844
| +4% | +$542K |
|
1025
Atour Lifestyle Holdings
ATAT
$4.5B
| $15.9M | ﹤0.01% |
883,921
+693,322
| +364% | +$12.7M |
|
Similar funds
T. Rowe Price Associates's Q1 2024 Portfolio in Review
As of Q1 2024, T. Rowe Price Associates held 3,021 positions worth $816B, up 9.6% from $744B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q1 2024 filing shows 108 new, 1,941 increased, 738 reduced and 64 closed positions. Its largest new stake was GE Vernova: 2,687,194 shares worth $367M. The largest sale was NVIDIA, an estimated $2.59B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2024 buy was GE Vernova: 2,687,194 shares worth $367M.
- T. Rowe Price Associates added most to Fortinet in Q1 2024, an estimated $2.03B increase.
- T. Rowe Price Associates's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $2.59B.
- T. Rowe Price Associates fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $621M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $816B portfolio in Q1 2024.
- T. Rowe Price Associates opened 108 new positions and closed 64 in Q1 2024.
- T. Rowe Price Associates's portfolio value rose 9.6% quarter-over-quarter to $816B.
Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.